Related Experiment Video
Updated: Apr 25, 2026
Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
Published on: September 16, 2020
High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins
Laia Tolosa1, Antonio Carmona2, José V Castell2,3,4
1Unidad de Hepatología Experimental, Torre A, Instituto Investigación Sanitaria La Fe (IIS La Fe), Bulevard Sur s/n, 46026, Valencia, Spain. laiatolosa@hotmail.com.
Abstract:
A frequent mechanism for drug-induced liver injury (DILI) is mitochondrial impairment, and early evaluation of new drugs for their potential to cause mitochondrial dysfunction is becoming an important task for drug development. To this end, we designed a high-content screening assay to study mitochondrial-induced hepatotoxicity in HepG2 cells in detail. Simultaneous assessment of mitochondrial mass and cell viability in cells exposed for 24 h to compounds provides preliminary information on the mitochondrial- or nonmitochondrial-related hepatotoxic potential of compounds. To fully address the mechanisms implicated in mitochondrial impairment, prelethal changes in mitochondrial superoxide production, mitochondrial membrane potential, mitochondrial permeability transition, intracellular calcium concentration and apoptotic cell death were studied in cells incubated for 1 h with compounds. The assay correctly classified a set of well-known mitochondrial toxicants and negative controls and revealed high sensitivity for the detection of mitochondrial DILI and the establishment of different mitochondrial toxicity risks (low to high). This procedure was used for analysing the potential mitochondrial impairment of six statins to determine their clinical risk. All the tested statins produced mitochondrial impairment, although they showed different levels of toxicity (low-medium toxicity risk). The results suggest that this cell-based assay is a promising in vitro approach to predict the potential of drug candidates to induce mitochondrial-associated hepatotoxicity.
Insights
A new assay effectively detects drug-induced liver injury by assessing mitochondrial dysfunction in liver cells. This method helps predict potential liver toxicity risks early in drug development.
Area of Science:
- Hepatotoxicity and Toxicology
- Mitochondrial Biology
- Drug Development
Background:
- Drug-induced liver injury (DILI) frequently involves mitochondrial impairment.
- Early assessment of mitochondrial dysfunction is critical for safe drug development.
- Existing methods may not fully capture the mechanisms of mitochondrial hepatotoxicity.
Purpose of the Study:
- To develop and validate a high-content screening assay for mitochondrial hepatotoxicity.
- To investigate mechanisms of mitochondrial impairment in HepG2 cells.
- To assess the mitochondrial toxicity of statins and predict clinical risk.
Main Methods:
- A high-content screening assay using HepG2 cells was designed.
- Simultaneous assessment of mitochondrial mass and cell viability after 24h compound exposure.
- Detailed analysis of prelethal mitochondrial changes (superoxide, membrane potential, permeability transition, calcium, apoptosis) after 1h incubation.
- Validation with known mitochondrial toxicants and negative controls.
Main Results:
- The assay accurately identified mitochondrial toxicants and negative controls.
- Demonstrated high sensitivity for detecting mitochondrial DILI.
- Classified compounds into different mitochondrial toxicity risk categories (low to high).
- All six tested statins induced mitochondrial impairment with varying low-to-medium toxicity risks.
Conclusions:
- The developed cell-based assay is a promising tool for predicting mitochondrial-associated hepatotoxicity.
- It enables early identification of potential DILI risks during drug development.
- The assay provides a mechanistic understanding of mitochondrial dysfunction induced by compounds.
More Related Videos
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug